
In this livestream, Dave breaks down new phase 3 retatrutide data, carefully contrasting idealized trial “efficacy estimate” numbers with more realistic “treatment regimen” outcomes, and explores what this means for real-world obesity care, dosing, and future multi-pathway combinations. He then shifts to news on high-dose Wegovy, safety concerns and fast-tracking of the oral GLP-1 orforglipron, and a detailed critique of the proposed Safe Drug Act of 2025, urging viewers to oppose it via a petition at otplinks.com because of its potential impact on access to compounded obesity medications.
Subscribe to your favorite podcasts and get free AI summaries within minutes of release.
Browse trending podcasts or search for your favorites
One click to follow any show — always free, no credit card
Free AI summaries delivered by email within minutes of release
Free forever · No credit card · Unsubscribe anytime
Never miss an episode of On The Pen With Dave Knapp. Subscribe for free →
No transcript available.